Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome
Open accessThe DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Alterations in sex hormones levels may lead to microbial dysbiosis which has been previously implicated in IBD and its symptom severity.(40)”
From Association Between Sex Hormone Levels and Gut Microbiota Composition and Diversity—A Systematic Review (2022) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 3×
“25% (fewer) of the mucosal microbial genes of healthy individuals [25].”
BackgroundInfluentialChanges of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087 · cited 1×
“The highest incidence rate has been recorded in developed countries, such as North America, Europe, Australia, and New Zealand [6], while recently, IBD has been gradually becoming more common in developing areas such as Asia and South America, and in developing countries such as including Brazil, South Korea, and Chin…”
BackgroundAssociation of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 2×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“Human Bacteroidetes Firmicutes, Enterobacteriaceae Decrease Increase [163]”
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030 · cited 1×
“The NOD2 (nucleotide-binding oligomerization domain containing protein 2), a first gene locus, has been reported as a risk locus for Crohn’s disease (CD) [175,176].”
BackgroundDiarrheagenic Escherichia coli
Nataro, J. P., & Kaper, J. B. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.1.142 · Cited by 5,006 · cited 1×
“Many studies in human IBD patients have reported the commensal bacteria association with the patient’s intestines; for example, an association of adherent/invasive Escherichia coli (AIEC), a normal gut flora of the Enterobacteriaceae group, has been found with CD [121].”
BackgroundMetabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“In addition, certain symbiotic gut microbiota members have been reported to have distinct and specific effects on the host immune system, and are considered key to immune homeostasis [31,37,38].”
BackgroundHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“Genome-wide association studies (GWAS) have identified more than 160 genetic loci associated with conferring protection from IBD or increased risk to IBD development [172].”
BackgroundRichness of human gut microbiome correlates with metabolic markers
Le Chatelier, E., Nielsen, T., Qin, J., Prifti, E., Hildebrand, F., Falony, G., Almeida, M., Arumugam, M., Batto, J.-M., Kennedy, S., et al. (2013) · Nature · doi:10.1038/nature12506 · Cited by 4,662
Research works printed but not linked: 2
- Zhang, 2007, Wumei pill decoction in the treatment of 72 cases of chronic nonspecific ulcerative colitis, Mod. J. Integr. Tradit. West. Med., 16, 5156
- Yan, 2013, Effect of Astragalus Polysaccharides on Th17/Treg Cytokines and Pulmonary Inflammation in Asthmatic Rats, Chin. Pharmacol. Bull., 29, 1275
Cited by
Items 701–800 of 804
ATHEROSCLEROTIC CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Kučerka, O., Malý, M., Mináriková, P., & Horáček, J. M. (2024) · Military Medical Science Letters · doi:10.31482/mmsl.2024.001
Jin, Y., Ma, X., Liu, J., Peng, H., Zhu, W., Jin, Z., Tao, M., Mei, L., & Yang, J. (2024) · Optical and Quantum Electronics · doi:10.1007/s11082-023-06171-z
“R As mentioned above, the incidence rate of inflammatory bowel disease is very high, and western medicine has its limitations, which still cannot be accepted by all patients (Khan et al. 2019).”
Retractedde Sant'Ana, D. N., Menezes, R. D. P., & Röder, D. V. D. D. B. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n2p1282-1310
Choi, H. S., Kim, D., Jang, Y.-J., Moon, J. S., & Oh, I. (2024) · Food Supplements and Biomaterials for Health · doi:10.52361/fsbh.2024.4.e3
Ulcerative colitis and pyoderma gangrenosum presentation of a case and brief literature review
Castillo, D. E. M., Ruiz, A. H., Medina, D. A. A., & Medina, R. D. L. C. (2023) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2023.14.00555
Caractérisation multi-omique des maladies inflammatoires de l’intestin
Pérez, K. (2021) · theses.fr (ABES) · doi:10.70675/460ea7f5zbfa9z4913zb273z073eee102f92
PROBIOTICOTERAPIA NA DOENÇA DE CROHN
de Oliveira, M. T. D. S., Martins, S. K. D. M., Moreira, I. P. M., Carvalho, H. M. D., Amorim, J. A., Silva, R. S. C., Oliveira, N. C. C. A., Oliveira, W. K. S., Alves, A. C. B. A., Costa, P. F. P., et al. (2024) · Even3 Publicações eBooks · doi:10.29327/5378061.1-4
The basic transcriptional machinery in intestinal homeostasis
Säisä-Borreill, S. (2021) · theses.fr (ABES) · doi:10.70675/79ec9f71z7f7cz480aza5e0z8a1f685e7960
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.25001638
胡, 志. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441099
Impact toxicologique de contaminants alimentaires au niveau intestinal et hépatique
Djouina, M. (2023) · theses.fr (ABES) · doi:10.70675/dd1f7d8azb7d6z4067z80c1z992dcbb60da4
A Comprehensive Analysis of Efficacy and Safety of Probiotics in Inflammatory Bowel Disease
Abraamyan, F., & Misra, N. (2024) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2024.146024
“…etiology of IBD remains unknown, research suggests that gut microbiome changes are considered one of the factors involved in disease progression: an altered immune response triggered by environmental factors targeting gut and gut microbiota in a genetically susceptible individual [4] [5] [6] [7].”
BackgroundHomoeopathic perceptions of gut dysbiosis as a clinically significant obstacle to cure
Hendriks, M. (2024) · DUT Open Scholar (Durban University of Technology) · doi:10.51415/10321/5587
Hazan, S., Bao, G., Vidal, A., & Sfera, A. (2024) · Cureus · doi:10.7759/cureus.75884 · Cited by 2
“Although, it remains unclear whether dysbiosis is the cause of IBD or a consequence of IBD [10,13,14].”
The Gut Microbiome: Unravelling Its Role in Digestive Health and Overall Wellness
Roychoudhuri, K., Santra, S., Goswami, R., & Pal, B. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-8267-7.ch008 · Cited by 2
Postbiotic effects on drug metabolism and therapeutic outcomes
Thangaraj, R., & Chellapandian, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22188-0.00017-6
An insight into probiotic microorganisms
Chaudhari, A., Pandey, S., & Dwivedi, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22188-0.00002-4 · Cited by 1
Commercially available human and animal postbiotics
Pandey, S., Chaudhari, A., & Dwivedi, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22188-0.00016-4
The Role of Microbiome in Nervous and Immune System Development
Wang, H., Lim, J. J., & Tang, Q. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00244-8
An update on gut microbiota: Its interaction with nutrients and metabolic syndrome
Haq, I. U., & Maham, S. (2025) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2025.08.001 · Cited by 1
Aftab, F., Shabbir, A., Safdar, I., Noor, A., Naveed, M., Mujahid, A. Y., Shuja, A., & Mudassar, M. (2025) · Kashf Journal of Multidisciplinary Research · doi:10.71146/kjmr576
Advances in our understanding of the lung-gut axis in tuberculosis
Colwell, S., & Cervantes, J. (2025) · FEMS Microbiology Letters · doi:10.1093/femsle/fnaf106
Awady, M. E. E., Hamed, A. A., Selim, M. S., Selim, H. M. R. M., Gomaa, F. A. M., Moustafa, N. M., El-Wakil, E. S., Mohamed, S. S., & Ghareeb, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26771-0.00034-5
Doença inflamatória intestinal: interação entre imunidade, microbiota e ambiente
Vieira, B. R., Zaparoli, A. S., DORTA, E. L., SOUSA, M. R. D., QUINTELA, N. I. M. D. S., MENEGATTI, M. G., ARCANJO, C. D. S. E. S., SILVA, A. B. D., SANTOS, S. S., Noronha, A., et al. (2025) · Editora Pasteur eBooks · doi:10.59290/0945219055
Imunologia & Doenças Infecciosas e Parasitárias Ed VIII
de Almeida, C. C., & de Freitas, G. B. L. (2025) · Editora Pasteur eBooks · doi:10.59290/978-65-6029-295-6
Kaden, T., Allwang, M., Stallhofer, J., Graf, K., Raasch, M., & Mosig, A. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1761539
“Therefore, emerging IBD therapies aim to improve the underlying microbial dysbiosis by restoring the microecology and metabolome pool, thereby preserving the host integrity through improved barrier function and immunomodulation (2, 9).”
Influence of Fusobacterium nucleatum on Tumor Necrosis Factor Alpha Therapy in Ulcerative Colitis
Şenyüz, B., Ünal, N. G., Doğanavşargıl, B., Uzel, A., Gündüz, C., & Süslüer, S. Y. (2025) · Mediators of Inflammation · doi:10.1155/mi/5035877 · Cited by 1
“Alterations in the composition and function (dysbiosis) of microbiota are being linked to various diseases [14].”
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.24940926
Ebrahiminejad, A., Sepahi, A. A., Yadegar, A., & Meyfour, A. (2024) · Figshare · doi:10.6084/m9.figshare.26241207
Zhou, J.-L., Bao, J.-C., Liao, X.-Y., Chen, Y., Wang, L., Fan, Y.-Y., Xu, Q., Hao, L.-X., Li, K.-J., Liang, M.-X., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24819551
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.26660113
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.26660122
Chen, K., McCulloch, J. A., Neves, R. D., Rodrigues, G., Hsieh, W.-T., Gong, W., Yoshimura, T., Huang, J., Ó’hUigín, C., Difilippantonio, S., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23529127
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.26667900
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605619
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605625
Rojas-Velázquez, D., Kidwai, S., Kraneveld, A. D., Tonda, A. P., Oberski, D. L., Garssen, J., & Lopez‐Rincon, A. (2024) · Figshare · doi:10.6084/m9.figshare.25001746
Wu, D., Zhang, Y., Zou, B., Lu, Y., & Cao, H. (2024) · Figshare · doi:10.6084/m9.figshare.26644738
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.26660119
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605622
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605610
Lin, A., Inman, R. D., Streutker, C., Zhang, Z., Pritzker, K. P. H., Tsui, H. W., & Tsui, F. W. L. (2020) · Figshare · doi:10.6084/m9.figshare.12004464
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605616
Hanscom, M., Loane, D. J., Aubretch, T., Leser, J. M., Molesworth, K., Hedgekar, N., Ritzel, R. M., Abulwerdi, G., Shea‐Donohue, T., & Faden, A. I. (2021) · Figshare · doi:10.6084/m9.figshare.13605613
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.26660116
Li, J., Wang, X., Wang, Q., Hu, Y., Wang, S., Xu, J., & Ye, J. (2024) · Figshare · doi:10.6084/m9.figshare.24940689
Characterizing the Role of SYK in the Pathogenesis of Inflammatory Disease
Mehta, M. (2021) · TSpace (University of Toronto)
Dixit, O. V. A. (2024) · Research Online (University of Wollongong)
Eficácia e efetividade da terapêutica biológica na doença de Crohn em doentes bio-naïve e não-naïve
Nunes, B. G. (2022) · Repositório Comum (Repositório Científico de Acesso Aberto de Portugal) · Cited by 1
Gancarčíková, S., Demečková, V., Lauko, S., Rynikova, M., Hajdučková, V., Gomulec, P., ADANDEDJAN, D., Petrovová, E., Kalanin, R., HULIK, S., et al. (2026) · Applied Sciences · doi:10.3390/app16020625
Stable plasmon-activated water innovatively applicable to restenosis prevention
Liu, T.-S., Pan, C., Liu, Y. H., & Wu, C. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119015
Exploring the impact of gut microbiota on epilepsy pathogenesis in Krushinsky–Molodkina rats
Bidzhiev, A. Z., Краева, Л. А., Ivlev, A. P., Goncharova, A. R., & Бажанова, Е. Д. (2025) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-eti-17934
“…bacteria, such as those belonging to the Clostridioides and Bacteroides genera, have been shown to possess anti-inflammatory and neuroprotective properties, while others, such a Prevotella copri, Escherichia and Shigella have been associated with pro-inflammatory effects [5, 10, 12, 21, 24, 26].”
The Gut-Brain Axis in Parkinson’s Disease: Probiotic Interventions and Mechanistic Insights
Hasnain, M. A., Bashir, H. H., & Moon, G. (2025) · Current Topic in Lactic Acid Bacteria and Probiotics · doi:10.35732/ctlabp.2025.11.2.41
Role of Pro-, Pre-, and Post-Biotic Targeting Gut Microbes for ROS Inhibition
Kaur, N., Kumar, S., Pandey, N. K., Baghel, D. S., Singh, S., Ashique, S., & Kumar, B. (2026) · Springer eBooks · doi:10.1007/978-3-032-11752-6_20
Burns, K. F., Blair, R. H., Mares, J. A., LaMonte, M. J., Wactawski‐Wende, J., McSkimming, D. I., Liu, Z., & Millen, A. E. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104635
The Analysis of Colonic Microbiome in Children with Dysbiotic Syndrome
Gavryliuk, V. G., Lavrentievа, K. V., Sklyar, T. (., & Slyshko, A. (. (2023) · Neliti
Gut Microbiota Dysbiosis and Probiotic Supplementation in IBD: A Narrative Review
Wandzel, M., Twardowska, D., Tłoczek, W., Tomczak, B., Topolski, K., Żukowiecka-Sęga, D., Śliwa, W., Jelonek, B., Klubikowska, K., & Porada, D. (2026) · Journal of Education Health and Sport · doi:10.12775/qs.2026.88.69386
Damm, G. K., Zhang, F., Koentgen, S., Jayawardana, T. C., Houshyar, Y., Read, S., Condous, G., El‐Assaad, F., & Hold, G. L. (2026) · iScience · doi:10.1016/j.isci.2026.115437
“45 This is consistent with our own findings, as IBD patients exhibited the lowest abundance of Blautia compared to the other patient groups.”
Astragalus Polysaccharide Improved DSS‐Induced Colitis in Mice By Remodeling the Gut Microbiota
KHAN, I. A., Bai, Y., Li, J., Wang, Z., Xu, Z., Yuan, T., Liu, X., Zhang, Y., Zhang, C., & Xu, S. (2026) · eFood · doi:10.1002/efd2.70141 · Cited by 1
Self-citationExploration du microbiote digestif par des approches multi-OMICS
Ngom, I. I. (2019) · theses.fr (ABES) · doi:10.70675/5cd8042ezb909z42b5z9024z3cb428057fe3
Fibrose intestinale, récepteur minéralocorticoide,alimentation.
Leboutte, M. (2023) · theses.fr (ABES) · doi:10.70675/a47cb697z212az4a17za4d6zeaf9d5cbaf24
Mariaule, V. (2024) · theses.fr (ABES) · doi:10.70675/1d41e841zf788z4dd7z8784zc26304e24ea1
Fargeas, M. (2024) · theses.fr (ABES) · doi:10.70675/cde34172z075cz4f4dza628z2707ac1ec2b7
Rahmah, R. A., & Mahmudiono, T. (2026) · PROFESSIONAL HEALTH JOURNAL · doi:10.54832/phj.v8i1.1190
“…it acts as a regulator of homeostasis by fermenting undigested complex polysaccharides, producing short-chain fatty acids (SCFAs), synthesizing certain vitamins, generating energy, preserving intestinal mucosal integrity, and protecting against pathogenic microorganisms (Khan et al., 2019).”
Bak, S.-G., Chandimali, N., Bae, J., Lee, D. Y., Lee, S. W., Park, E. J., Lim, H. J., Won, Y., Rho, M. C., & Lee, S.-J. (2026) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2026.04.006
Jena, P. K., MOHAPATRA, P. K. D., Rahaman, S. M., Das, S., Rahman, S., Mustaq, S., & Barık, D. P. (2026) · Environmental Processes · doi:10.1007/s40710-026-00830-5
“Any alteration in the gut microbiota structural composition that can disturb the microbial equilibrium is termed “dysbiosis” and is connected with a number of gut diseases (Khan et al. 2019).”
Postbiotics – The Future of a Healthy Microbiome: A Review
Salkić, A., Zumreta, B. K., Mujezin, L., Almira, A., Josip, B., Oras, A., & Žuljević, S. O. (2026) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-06531-5_95
Postbiotics - The Future of a Healthy Microbiome: A Review
Salkić, A., Zumreta, B. K., Mujezin, L., Almira, A., Josip, B., Oras, A., & Žuljević, S. O. (2026) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-032-06531-5_2
Sandra, F., Scania, A. E., Dewi, N. M., Ranggaini, D., Halim, J., Pakpahan, A., & Lee, K. H. (2026) · International Journal of Microbiology · doi:10.1155/ijm/5597426
An Emerging Approach to IBD Treatment: Personalized Nutrition Through Gut Microbiome Optimization
Yusuf, K., Attard, T. M., Al-Kasspooles, M., & Umar, S. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl47779
Huang, J. G., Tay, C. J. X., Aw, M., Lee, Y.-S., & Ooi, D. S. Q. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.120066
Shirima, C. A., Sabuholo, G., Bubulac, L., Patel, P., & Pîrcălăbioru, G. G. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.119352
Sun, Z., Yuan, M., Wang, X., Li, M., Wang, X., Li, Y., Zhang, T., Liu, Q., & Zhang, X. (2026) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2026.06.001
Surface-coated probiotics: engineered living platforms for targeted IBD therapy
Li, H., Cong, J., Wang, K., Wen, C., Xu, L., Xu, X., Zhang, Y., & Liang, Y. (2026) · Advanced Composites and Hybrid Materials · doi:10.1007/s42114-026-01920-6
Detman, A., Schiro, G., Filip, R., Samborowska, E., Karczmarski, J., Jarmakiewicz-Czaja, S., Jakubowska, K., Williams, A., Hickman, N., Laubitz, D., et al. (2026) · Microbial Cell Factories · doi:10.1186/s12934-026-03052-4
Hu, H., Yao, X., Zhou, H., Wang, L., Peng, B., Liu, C., Luo, S., Huang, J., & Min, X. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1896924
“Inflammation in UC not only reduces microbial diversity but also alters the composition of specific bacterial communities (Ni et al., 2017; Franzosa et al., 2019; Khan et al., 2019; Tian et al., 2020).”
Gómez, D. P. (2021) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Glazier, J., Villegas, D., McClure, S., Ghali, J., Fuerte-Stone, J., & Mimee, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.744002
“Inflammation causes well-115 documented, multifaceted changes to the gut biochemical landscape, including shifts in metabolites and SCFAs 48 , alterations in host immune responses, and barrier integrity failure 3,5,6,49 .”
Tablawy, M., Ibrahim, A. A., Badawi, A. A., Jairamani, S., Fatima, N., Eldeeb, A., Anbar, O., Mohamed, A. A., Mohamed, A. H., Abouzahra, M. M., et al. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02059-3 · Cited by 2
“Diabetes-induced dysbiosis of the gut microbiome, characterized by reduced abundance of protective Faecali - bacterium prausnitzii and enrichment of pathogenic Esch - erichia coli and Fusobacterium, further perpetuates mucosal inflammation and barrier dysfunction [35 ].”
Wang, J., Ouyang, S., Tan, Z., Jia, Y., Li, J., Chen, Y., Tong, B., Dai, J., Wang, M., & Xu, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115329
Loor, C. S. M., & Guerra, J. B. A. (2026) · Revista Científica de Salud BIOSANA · doi:10.62305/biosana.v6i4.1255
Determinants of enteric hyperoxaluria in the SAMP1/YitFc mouse model of spontaneous ileitis
Zaidan, N., Jaber, K., Ho, M., Zhou, B., Pei, Z., Bui, M. L., Cardozo, L., Merritts, K., Mishra, R., Xiong, X., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2725367
“37 Across all three diets, SAMP1 mice exhibited an enrichment of species such as Bacteroides, Lactobacillus, Alistipes, and Enterococcus .”
Kazi, N., Ansari, N., Zobairi, A., & Vaali‐Mohammed, M. (2026) · Microbes & Immunity · doi:10.36922/mi026120027
Frandeș, S. I., Frandes, O., Macarie, M., & Bataga, S. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187270
周丽娜, Chen, Y., Liu, M., Wu, M., Deng, H., Miao, Z., Wang, X., Zhang, C., Hua, K., Guan, C., et al. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1976594
“Therefore, therapeutic strategies that target oxidative stress and modulate inflammatory pathways could offer significant promise for the effective management of IBD (Kim and Chang, 2014; Khan et al., 2019).”
Self-citationDagah, O. M. A., Ullah, Z., Alhameed, A. M. M., Al-Azzani, H., Manzoor, R., Khamis, M. Y., Liu, Z., & Lu, J. (2026) · Molecular Immunology · doi:10.1016/j.molimm.2026.09.009
Experiences on dietary guidance among people with inflammatory bowel disease
Kauppila, H. (2024) · UEF eRepo (University of Eastern Finland)
Letizia, C. (2023) · Nutrimentum et Curae
Evolution of the blood microbiome in primates
Valizadegan, N. (2022) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Metadata
- Authors
- Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C.
- Affiliations
- Lanzhou University (CN)
- Gansu Key Laboratory of Functional Genomics and Molecular Diagnosis, Lanzhou 730000, China
- Corresponding author
- Zhang, Chunjiang
- Venue
- Pathogens
- Publisher
- MDPI AG
- Published
- 2019-08-13
- Volume
- 8
- Issue
- 3
- Pages
- 126
- ISSN
- 2076-0817 (ISSN-L)
- PMC
- PMC6789542
- OpenAlex
- W2966933380
- Cited by
- 771
- References
- 267
- Citations by year
- 2026: 43 · 2025: 105 · 2024: 149 · 2023: 134 · 2022: 135 · 2021: 132 · 2020: 66 · 2019: 7
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-sa)
- Lanzhou University Institutional Repository (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Jiangsu Science and Technology Major Project ((No. BA2016036))
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- inflammatory bowel disease, gut microbiota, dysbiosis, Crohn's disease, ulcerative colitis, intestinal inflammation, microbiota-based therapy, probiotics, prebiotics, mouse colitis model, IBD pathogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.